CN100413496C - 丁二酸衍生物酯类化合物在制备治疗痴呆症的药物中的用途 - Google Patents
丁二酸衍生物酯类化合物在制备治疗痴呆症的药物中的用途 Download PDFInfo
- Publication number
- CN100413496C CN100413496C CNB2003801078643A CN200380107864A CN100413496C CN 100413496 C CN100413496 C CN 100413496C CN B2003801078643 A CNB2003801078643 A CN B2003801078643A CN 200380107864 A CN200380107864 A CN 200380107864A CN 100413496 C CN100413496 C CN 100413496C
- Authority
- CN
- China
- Prior art keywords
- dementia
- chemical compound
- group
- mice
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 33
- 150000002148 esters Chemical class 0.000 title 1
- 230000013016 learning Effects 0.000 claims abstract description 31
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 64
- 208000024827 Alzheimer disease Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 15
- 150000003443 succinic acid derivatives Chemical class 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 49
- 241001465754 Metazoa Species 0.000 abstract description 44
- -1 succinate derivative esters Chemical class 0.000 abstract description 39
- 241000700159 Rattus Species 0.000 abstract description 22
- 238000002474 experimental method Methods 0.000 abstract description 21
- 230000002146 bilateral effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 abstract description 11
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 abstract description 11
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 abstract description 11
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 abstract description 11
- 229960002646 scopolamine Drugs 0.000 abstract description 11
- 230000007087 memory ability Effects 0.000 abstract description 8
- 241000582790 Dactylorhiza viridis Species 0.000 abstract description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 102000003914 Cholinesterases Human genes 0.000 abstract 1
- 108090000322 Cholinesterases Proteins 0.000 abstract 1
- 229940048961 cholinesterase Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 50
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 21
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 21
- 239000001301 oxygen Substances 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 238000011534 incubation Methods 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 15
- 230000009189 diving Effects 0.000 description 15
- 229960004373 acetylcholine Drugs 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- 210000004534 cecum Anatomy 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000001168 carotid artery common Anatomy 0.000 description 9
- 230000005611 electricity Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100033639 Acetylcholinesterase Human genes 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000357202 Dendrobium linguiforme Species 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 206010013395 disorientation Diseases 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000007 protein synthesis inhibitor Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 101150060184 ACHE gene Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 241000732800 Cymbidium Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000305492 Gastrodia Species 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001951 hemoperfusion Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002664 nootropic agent Substances 0.000 description 2
- 230000001777 nootropic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 108010080213 vascular factor Proteins 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- YPHMISFOHDHNIV-UHFFFAOYSA-N 4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]piperidine-2,6-dione Chemical compound C1C(C)CC(C)C(=O)C1C(O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-UHFFFAOYSA-N 0.000 description 1
- 241000608073 Anacamptis papilionacea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000171728 Cyrtosia septentrionalis Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000608360 Dactylorhiza Species 0.000 description 1
- 241000582794 Dactylorhiza incarnata Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000741854 Galeola Species 0.000 description 1
- 241000904118 Galeola faberi Species 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000608162 Himantoglossum hircinum Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 244000061661 Orchis Species 0.000 description 1
- 244000050492 Orchis militaris Species 0.000 description 1
- 235000016008 Orchis militaris Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001516476 Vanda Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | 潜伏期(秒) | 受电击次数 |
假手术组 | 156±35 | 1.3±0.3 | |
模型组 | 30±14## | 1.6±0.2 | |
CE | 5 | 118±34<sup>*</sup> | 1.4±0.3 |
W6 | 1 | 110±37<sup>*</sup> | 0.9±0.2 |
组别 | 剂量(mg/kg) | 游出时间(秒) | 进入盲端次数 |
假手术组 | 34±8 | 4.3±1.1 | |
模型组 | 62±10# | 6.4±1.1# | |
CE | 5 | 36±10<sup>*</sup> | 3.1±1.4<sup>*</sup> |
W6 | 1 | 46±11 | 3.1±0.8<sup>*</sup> |
分组 | 剂量(mg/kg) | 潜伏期(秒) | 受电击次数 |
假手术组 | 256±40 | 0.3±0.2 | |
模型组 | 125±38# | 0.9±0.2# | |
CE | 5 | 245±30<sup>*</sup> | 0.2±0.2<sup>*</sup> |
W6 | 1 | 253±31<sup>*</sup> | 0.2±0.1<sup>*</sup> |
分组 | 剂量(mg/kg) | 游出时间(秒) | 进入盲端次数 |
假手术组 | 25±14 | 4.0±0.3 | |
模型组 | 51±24## | 7.5±0.7# | |
CE | 5 | 22±11<sup>***</sup> | 4.3±0.5<sup>*</sup> |
W6 | 1 | 33±19<sup>*</sup> | 5.4±1.4 |
分组 | ACHE活性 | 抑制率(%) |
正常对照组 | 0.72±0.18 | -- |
石杉碱甲1mg/kg | 0.48±0.10<sup>*</sup> | 34 |
CE 5mg/kg | 0.77±0.20 | 0 |
W6 5mg/kg | 0.80±0.16 | 0 |
W6 20mg/kg | 0.72±0.16 | 0 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003801078643A CN100413496C (zh) | 2002-12-31 | 2003-12-31 | 丁二酸衍生物酯类化合物在制备治疗痴呆症的药物中的用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02159342.6 | 2002-12-31 | ||
CNA021593426A CN1511520A (zh) | 2002-12-31 | 2002-12-31 | 丁二酸酯衍生物治疗痴呆症的用途 |
CNB2003801078643A CN100413496C (zh) | 2002-12-31 | 2003-12-31 | 丁二酸衍生物酯类化合物在制备治疗痴呆症的药物中的用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100846994A Division CN101015648B (zh) | 2002-12-31 | 2003-12-31 | 含有丁二酸衍生物酯类化合物的凹舌兰提取物在制备用于治疗痴呆症的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1731991A CN1731991A (zh) | 2006-02-08 |
CN100413496C true CN100413496C (zh) | 2008-08-27 |
Family
ID=32661095
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA021593426A Pending CN1511520A (zh) | 2002-12-31 | 2002-12-31 | 丁二酸酯衍生物治疗痴呆症的用途 |
CN2007100846994A Expired - Lifetime CN101015648B (zh) | 2002-12-31 | 2003-12-31 | 含有丁二酸衍生物酯类化合物的凹舌兰提取物在制备用于治疗痴呆症的药物中的用途 |
CNB2003801078643A Expired - Lifetime CN100413496C (zh) | 2002-12-31 | 2003-12-31 | 丁二酸衍生物酯类化合物在制备治疗痴呆症的药物中的用途 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA021593426A Pending CN1511520A (zh) | 2002-12-31 | 2002-12-31 | 丁二酸酯衍生物治疗痴呆症的用途 |
CN2007100846994A Expired - Lifetime CN101015648B (zh) | 2002-12-31 | 2003-12-31 | 含有丁二酸衍生物酯类化合物的凹舌兰提取物在制备用于治疗痴呆症的药物中的用途 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7557089B2 (zh) |
EP (1) | EP1582209B1 (zh) |
JP (1) | JP4880223B2 (zh) |
KR (1) | KR100855389B1 (zh) |
CN (3) | CN1511520A (zh) |
AU (1) | AU2003292876A1 (zh) |
BR (1) | BR0317217A (zh) |
CA (1) | CA2512187C (zh) |
ES (1) | ES2395725T3 (zh) |
IL (1) | IL169489A0 (zh) |
RU (1) | RU2334524C2 (zh) |
WO (1) | WO2004058244A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104884052A (zh) * | 2012-12-31 | 2015-09-02 | 切萨联盟有限公司 | 4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用于预防及治疗认知、神经退行性或神经元疾病 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0708507D0 (en) | 2007-05-02 | 2007-06-13 | Queen Mary & Westfield College | Substituted phosphonates and their use |
RU2504367C1 (ru) * | 2012-06-05 | 2014-01-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Амурская государственная медицинская академия" Минздравсоцразвития Российской Федерации | Способ коррекции психического состояния пациентов и антиоксидантного статуса при органическом расстройстве личности |
CN104781390B (zh) | 2012-08-16 | 2017-07-28 | 庆熙大学校产学协力团 | 具有对衰老及痴呆的预防和/或治疗活性的乳酸菌 |
US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
CN109160928B (zh) * | 2017-09-21 | 2020-07-21 | 暨南大学 | 辣木籽中新的酚苷类化合物及其应用 |
CN108690104B (zh) * | 2018-05-08 | 2020-11-20 | 北京理工大学 | 一类葡萄糖氧基苄酯类化合物、其制备方法及其应用 |
CN110698531B (zh) * | 2019-11-01 | 2020-11-03 | 首都医科大学附属北京中医医院 | 一种用于改善微循环障碍的新化合物及其制法 |
CN110787172B (zh) * | 2019-12-13 | 2022-07-01 | 中央民族大学 | 洛罗兰糖苷在制备防治糖尿病的药物中的应用以及一种防治糖尿病的药物 |
CN113730425B (zh) * | 2021-09-06 | 2023-05-23 | 北京斯利安健康科技有限公司 | 含叶酸的组合物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1306857A (zh) * | 1999-05-25 | 2001-08-08 | 青海省老年医学研究所 | 一种强身健体、增强机体免疫功能的药 |
-
2002
- 2002-12-31 CN CNA021593426A patent/CN1511520A/zh active Pending
-
2003
- 2003-12-31 CN CN2007100846994A patent/CN101015648B/zh not_active Expired - Lifetime
- 2003-12-31 AU AU2003292876A patent/AU2003292876A1/en not_active Abandoned
- 2003-12-31 US US10/541,082 patent/US7557089B2/en not_active Expired - Lifetime
- 2003-12-31 EP EP03782083A patent/EP1582209B1/en not_active Expired - Lifetime
- 2003-12-31 JP JP2004562475A patent/JP4880223B2/ja not_active Expired - Lifetime
- 2003-12-31 ES ES03782083T patent/ES2395725T3/es not_active Expired - Lifetime
- 2003-12-31 CN CNB2003801078643A patent/CN100413496C/zh not_active Expired - Lifetime
- 2003-12-31 KR KR1020057012335A patent/KR100855389B1/ko not_active IP Right Cessation
- 2003-12-31 WO PCT/CN2003/001155 patent/WO2004058244A1/zh active Application Filing
- 2003-12-31 RU RU2005124275/15A patent/RU2334524C2/ru active
- 2003-12-31 CA CA2512187A patent/CA2512187C/en not_active Expired - Lifetime
- 2003-12-31 BR BR0317217-1A patent/BR0317217A/pt not_active Application Discontinuation
-
2005
- 2005-06-30 IL IL169489A patent/IL169489A0/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1306857A (zh) * | 1999-05-25 | 2001-08-08 | 青海省老年医学研究所 | 一种强身健体、增强机体免疫功能的药 |
Non-Patent Citations (4)
Title |
---|
藏药旺拉化学成分的研究. 黄胜阳,石建功,杨永春等.中国中药杂志,第27卷第2期. 2002 |
藏药旺拉化学成分的研究. 黄胜阳,石建功,杨永春等.中国中药杂志,第27卷第2期. 2002 * |
长苞凹舌兰化学成分研究. 黄胜阳,石建功,杨永春等.药学学报,第37卷第3期. 2002 |
长苞凹舌兰化学成分研究. 黄胜阳,石建功,杨永春等.药学学报,第37卷第3期. 2002 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104884052A (zh) * | 2012-12-31 | 2015-09-02 | 切萨联盟有限公司 | 4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用于预防及治疗认知、神经退行性或神经元疾病 |
CN104884052B (zh) * | 2012-12-31 | 2021-06-25 | 切萨联盟有限公司 | 4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用于预防及治疗认知、神经退行性或神经元疾病 |
Also Published As
Publication number | Publication date |
---|---|
WO2004058244A1 (fr) | 2004-07-15 |
CA2512187C (en) | 2011-03-01 |
US7557089B2 (en) | 2009-07-07 |
KR100855389B1 (ko) | 2008-09-04 |
RU2334524C2 (ru) | 2008-09-27 |
CA2512187A1 (en) | 2004-07-15 |
JP2006512373A (ja) | 2006-04-13 |
BR0317217A (pt) | 2005-11-01 |
IL169489A0 (en) | 2007-07-04 |
EP1582209A4 (en) | 2010-02-10 |
EP1582209B1 (en) | 2012-09-19 |
RU2005124275A (ru) | 2006-01-20 |
CN1511520A (zh) | 2004-07-14 |
CN101015648A (zh) | 2007-08-15 |
JP4880223B2 (ja) | 2012-02-22 |
CN101015648B (zh) | 2010-05-26 |
KR20050085934A (ko) | 2005-08-29 |
US20060281692A1 (en) | 2006-12-14 |
EP1582209A1 (en) | 2005-10-05 |
ES2395725T3 (es) | 2013-02-14 |
AU2003292876A1 (en) | 2004-07-22 |
CN1731991A (zh) | 2006-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100502858C (zh) | 柚皮素及其衍生物用于制备抗心脑系统疾病产品的用途 | |
EP1024146B1 (en) | Use of a steroid saponin for the treatment of dementia | |
US9125926B2 (en) | Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent | |
CN103059043A (zh) | 伸筋草碱a-c、其制法和其药物组合物与用途 | |
JPH04504414A (ja) | 老人性痴呆症治療用組成物及びその治療方法 | |
CN100413496C (zh) | 丁二酸衍生物酯类化合物在制备治疗痴呆症的药物中的用途 | |
CN1863523A (zh) | 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用 | |
Ellis et al. | Adjunct to bile-acid treatment for gall-stone dissolution: low-dose chenodeoxycholic acid combined with a terpene preparation. | |
AU2015384083B2 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
CN109942491B (zh) | 附子中具有抗炎镇痛作用的c20二萜生物碱及其用途 | |
CN106905281A (zh) | 厚果崖豆藤中抑制乙酰和丁酰胆碱酯酶的黄酮类化合物及其用途 | |
CN110314233B (zh) | 包含柠檬苦素类化合物和dpp-4抑制剂的组合产品 | |
CN101385736A (zh) | 芍药苷在预防和治疗抑郁症药物中的应用及其药物组合物 | |
TW201424746A (zh) | 用以治療腸激躁症之山薑屬植物萃取物 | |
CN102631397B (zh) | 一种改善脑部血液循环的中药组合物及其制备方法 | |
CN114949070A (zh) | 鹿茸草有效部位提取物在制备治疗炎性疾病或肿瘤药物中的应用 | |
CN100464760C (zh) | 苍耳子总苷提取物用于制备抗炎性反应产品的用途 | |
CN1994352A (zh) | 苍耳子总苷提取物用于制备抗炎性反应产品的用途 | |
CN101974012B (zh) | 一种具有药用活性的新化合物灯盏细辛酸乙酯 | |
CN102526157A (zh) | 红花提取物在预防或治疗神经退行性疾病中的用途 | |
KR100547253B1 (ko) | 암 예방 및 치료에 유효한 진세노사이드 유도체 | |
CN101461803B (zh) | 葡萄内酯的用途 | |
KR20140056651A (ko) | 지방산을 유효성분으로 하는 히스타민 수용체 길항제 조성물 | |
KR101456953B1 (ko) | 이카리시드 ii의 남성 또는 여성 성기능장애의 예방 또는 치료제 제조에서의 용도 | |
CN103845339B (zh) | 泽泻醇a在制备抗动脉粥样硬化药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING LIANXIN PHARMACEUTIC CO., LTD. Free format text: FORMER OWNER: PHARMACOLOGY INST. OF CAMS Effective date: 20140603 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: XUANWU, BEIJING TO: 102600 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140603 Address after: 102600 Daxing District Beijing biological engineering and pharmaceutical industry base, 9 Fu Tian Street Patentee after: BEIJING LIANXIN PHARMACEUTICAL Co.,Ltd. Address before: Beijing City, Xuanwu District Chinese xiannongtan street, Patentee before: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20080827 |